Aqtual

High-Level Overview

Aqtual is a precision medicine company developing blood-based diagnostic tests for chronic diseases and oncology using a novel cell-free DNA (cfDNA) platform that analyzes epigenetics, gene regulation, and transcriptomics from a single blood draw.[1][2][3] It serves patients with conditions like rheumatoid arthritis (RA) by predicting therapy responses, addressing the problem of ineffective treatments in costly disease areas where patients often fail expensive therapies without clear guidance.[1][4] The company has shown strong growth momentum, raising $16M in Series A funding in 2023 and an oversubscribed $31M Series B in July 2025 to advance its RA therapy response test toward commercialization in 2026.[2][3][5]

Origin Story

Aqtual was co-founded by Diana Abdueva, Ph.D., who serves as CEO, leveraging her expertise to pioneer a platform that captures "noise" in cfDNA—previously overlooked fragments revealing regulatory insights into gene expression and disease mechanisms.[3][4] The idea emerged from breakthroughs in proprietary biochemistry and data science, enabling analysis of circulating chromatin in blood to bridge research and clinical use, starting with RA where patients frequently switch therapies due to non-response.[1][3] Early traction came via a pilot study identifying RA treatment response biomarkers, followed by a prospective clinical study in diverse patients, fueling rapid funding: $16M Series A co-led by Genoa Ventures, Manta Ray Ventures, and Yu Galaxy in October 2023.[3]

Core Differentiators

• Novel cfDNA Platform: First to integrate DNA, epigenetics, and protein-DNA binding in one blood assay, profiling 200,000 gene promoters, 400,000 enhancers, and more for tissue-specific insights, surpassing prior methods limited to basic sequencing.[1][3][4]
• Clinical Applications: Focuses on real-time disease monitoring and therapy prediction, e.g., RA test stratifies patients to avoid ineffective drugs, validated in pilots with plans for larger studies.[1][2]
• Data-Driven Precision: Uses advanced analytics on active chromatin cfDNA for holistic views of disease, microenvironment, and immune response, enabling applications across RA, oncology, and other inflammatory conditions.[1][4]
• Scalability and Partnerships: Backed by diagnostics strategics and VCs like Bold Capital, positioning for broad commercialization and pipeline expansion.[2][4]

Role in the Broader Tech Landscape

Aqtual rides the precision medicine wave in liquid biopsies, where cfDNA diagnostics are shifting from oncology to chronic diseases amid rising healthcare costs and demand for personalized therapies.[2][3][5] Timing aligns with maturing epigenetics tools and post-pandemic focus on efficient monitoring, as RA alone affects millions with high non-response rates to biologics.[1] Market forces like aging populations and drug pricing pressures favor non-invasive tests that optimize treatments, reducing trial-and-error; Aqtual influences the ecosystem by open-sourcing new biomarkers and partnering with VCs to accelerate cfDNA adoption beyond cancer.[4]

Quick Take & Future Outlook

Aqtual is poised to launch its RA therapy prediction test in 2026, triggering Series C fundraising amid a diagnostics boom, with potential expansion to oncology and other chronics via its versatile platform.[2][5] Trends like AI-enhanced genomics and value-based care will amplify its edge, evolving its role from pioneer to ecosystem enabler through partnerships and data catalogs that redefine chronic disease management.[1][4] This positions Aqtual to transform precision medicine from research promise to frontline reality, directly tackling the translational gaps it was built to bridge.